AIM
BIIB icon

Achmea Investment Management’s Biogen BIIB Stock Holding History

Achmea Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,169
Closed -$303K – 428
2023
Q4 		$303K Sell
1,169
-21,733
-95% -$5.34M 0.01% 474
2023
Q3 		$5.89M Sell
22,902
-961
-4% -$257K 0.13% 180
2023
Q2 		$6.8M Buy
23,863
+2,473
+12% +$736K 0.14% 160
2023
Q1 		$5.95M Buy
21,390
+2,884
+16% +$798K 0.17% 146
2022
Q4 		$4.8M Buy
18,506
+9,534
+106% +$2.69M 0.16% 159
2022
Q3 		$2.4M Buy
8,972
+232
+3% +$49.3K 0.08% 246
2022
Q2 		$1.78M Hold
8,740
– – 0.06% 302
2022
Q1 		$1.84M Buy
8,740
+258
+3% +$56.1K 0.05% 346
2021
Q4 		$2.03M Sell
8,482
-1,002
-11% -$258K 0.1% 189
2021
Q3 		$2.68M Sell
9,484
-1,518
-14% -$498K 0.08% 286
2021
Q2 		$3.81M Sell
11,002
-7,495
-41% -$2.27M 0.13% 215
2021
Q1 		$5.17M Sell
18,497
-3,834
-17% -$1.03M 0.18% 158
2020
Q4 		$5.47M Sell
22,331
-16,164
-42% -$4.17M 0.2% 141
2020
Q3 		$10.9M Sell
38,495
-46,957
-55% -$13.1M 0.46% 45
2020
Q2 		$22.9M Buy
85,452
+19,522
+30% +$5.87M 0.77% 28
2020
Q1 		$20.9M Buy
65,930
+45,585
+224% +$13.8M 0.96% 19
2019
Q4 		$6.04M Sell
20,345
-9,535
-32% -$2.65M 0.23% 106
2019
Q3 		$6.96M Sell
29,880
-3,551
-11% -$827K 0.27% 92
2019
Q2 		$7.82M Buy
33,431
+6,015
+22% +$1.39M 0.3% 79
2019
Q1 		$6.48M Buy
27,416
+1,627
+6% +$512K 0.27% 89
2018
Q4 		$7.76M Buy
25,789
+4,680
+22% +$1.49M 0.36% 64
2018
Q3 		$7.45M Sell
21,109
-3,236
-13% -$1.11M 0.28% 81
2018
Q2 		$7.06M Hold
24,345
– – 0.25% 107
2018
Q1 		$6.66M Sell
24,345
-1,055
-4% -$327K 0.22% 113
2017
Q4 		$8.09M Buy
25,400
+10,314
+68% +$3.31M 0.27% 93
2017
Q3 		$4.72M Buy
15,086
+3,569
+31% +$1.06M 0.27% 92
2017
Q2 		$3.12M Sell
11,517
-10,005
-46% -$2.65M 0.19% 140
2017
Q1 		$5.88M Buy
+21,522
New +$6.09M 0.28% 94

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Achmea Investment Management's BIIB Position: Q1 2024 in Review

Achmea Investment Management sold out of Biogen (BIIB) in Q1 2024, closing a stake of 1,169 shares — an estimated $303K sold.

Achmea Investment Management first reported a position in BIIB in Q1 2017 and held it in 28 quarters. The position peaked at $22.9M in Q2 2020. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

  • Achmea Investment Management reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
  • Achmea Investment Management sold 1,169 Biogen shares in Q1 2024, an estimated $303K.
  • Achmea Investment Management first reported a position in Biogen in Q1 2017 and held it in 28 quarters.
  • Achmea Investment Management's Biogen position peaked at $22.9M in Q2 2020.
  • 955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Achmea Investment Management's 13F filing for Q1 2024, filed 8 May 2024.